3 results match your criteria: "Itami Kidney Clinic[Affiliation]"
Article Synopsis
- The study aimed to investigate the effectiveness of nemolizumab, an anti-IL-31 receptor antibody, in treating uremic pruritus in Japanese hemodialysis patients, comparing it to a placebo and an oral medication, nalfurafine.
- Patients were divided into multiple groups receiving different doses of nemolizumab or placebo, with the primary goal being to measure changes in itching severity after 4 weeks.
- The results showed that while some patients noticed improvements in itching, the primary endpoint of significant efficacy was not achieved, although nemolizumab was generally well-tolerated without major safety issues.
Background: Intermittent infusion hemodiafiltration -(I-HDF) using repeated infusion of ultrapure dialysis fluid through a dialysis membrane or sterile nonpyrogenic substitution fluid was developed to prevent a rapid decrease in blood pressure by increasing the patient's circulating blood volume, to enhance the plasma refilling rate by improving peripheral circulation, and to enhance solute transfer from the extravascular space to the intravascular space by enhancing the plasma refilling rate. Furthermore, the effect of fouling caused by attachment of proteins to the membrane as a result of ultrafiltration can be reduced by backflushing of the membrane with the purified dialysate in I-HDF. Although there have been several clinical trials of I-HDF, there have been no comparisons of the clinical significance of and indications for -I-HDF with those of conventional hemodialysis (HD).
View Article and Find Full Text PDFEffect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.
JAMA
December 2018
Hemodialysis Center, Inoue Hospital, Soryu Medical Corporation, Osaka, Japan.
Article Synopsis
- Patients with chronic kidney disease have a higher cardiovascular risk and impaired vitamin D activation, leading researchers to investigate the effects of vitamin D receptor activators on health.
- A randomized study involving 1,289 patients on hemodialysis aimed to assess whether oral alfacalcidol could reduce cardiovascular events and mortality compared to a control group.
- The results showed that, over an average follow-up of 4 years, a significant portion of patients experienced cardiovascular events, highlighting the potential importance of active vitamin D treatment for improving patient outcomes in this population.